We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.62 | -8.83% | 6.40 | 6.00 | 6.80 | 6.80 | 6.64 | 6.66 | 863,426 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.78 | 13.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/3/2020 20:44 | Anyone have access to Pharma Letter? Headline: Synairgen’s SNG001 will prevent cell damage in fight against coronavirus pandemic | davew28 | |
21/3/2020 17:55 | Coronavirus: New treatment for critically ill patients to begin trials as soon as next week The inhaled drug can already help asthma and chronic obstructive pulmonary disease patients with other lung infections. The experimental drug, code named SNG001, will initially be given to patients at Southampton General Hospital as part of the first trial of its kind. Doctors have high hopes that it could also help stop the coronavirus in its tracks. The inhaled treatment has already been shown to improve the recovery of asthma and COPD (chronic obstructive pulmonary disease) patients who have other lung infections . . . . . . hxxps://news.sky.com | bmnsa | |
21/3/2020 17:43 | thwarnts If only. I'm closing other positions and going all out with SNG. | bmnsa | |
21/3/2020 17:30 | See Trump was talking about FDA fast tracking therapeutics to deal with the situation now. | talk2dubya | |
21/3/2020 15:48 | Surely the MM's are going to come looking for those stop losses in the next 2 weeks, any major drop IMV is a massive BUY signal. GL to holders | thwarnts | |
21/3/2020 15:31 | Apparently people are overdosing in Nigeria from chloroquine at the moment (available freely because of malaria). | talk2dubya | |
21/3/2020 15:26 | Interesting news re treatment.....Hydrox Quite curious, because these were never designed to treat viruses in general. Perhaps the next step in the evolution of therapy is the combination of HC/Azith and Inhaled SNG001 | yet another final | |
21/3/2020 15:17 | A big plus for this share is only 44.2% of shares are deemed to be in public hands!22m trades in last 2 days average 11m bought and 11m sold out of 48m available in public hands!This indicates to me that we could have a severe upward squeeze if there is any positive announcement on Monday | dave444 | |
21/3/2020 14:35 | It's in the polish news as well! :-)https://pharmatre | no1larafan | |
21/3/2020 14:09 | My thoughts... Re share price movements, and all things being equal, anticipate a early morning spike of 20 to 30% followed by a 'usual' walk down to about low 50s then a gradual rising price closing around 60+/-5All bets off if new positive news available re SNG001 | yet another final | |
21/3/2020 14:07 | Thanks again to you, all the best and yes I am another sport lover, football and cricket, tennis, so life is rotten with nothing to look forward to, even playing tennis is coming to an end for the present | lukead | |
21/3/2020 14:03 | Treatment is different from Cure | yet another final | |
21/3/2020 14:00 | One is for diagnosis and the other is for treatmentNCYT is a diagnostic test, and is only as valuable as the government's strategy in dealing with crisis. I believe NCYT was going to be massive, had the government gone ahead and did mass testing to identify those with the virus (regardless of symptoms) and isolate them (put them in leper colonies) then we would not have had the rising numbers..... Anyway the opted to let the virus spread and hope people get immunity.... But that means people getting infected!!! So scope of diagnosis may have been curtailed (millions instead of 100s of millions) Treatment for Covid will require multiple agents depending on severity and symptoms. I believe that SNG001, with proven benefit in reducing viral load (see their website) will, once researched and approved, will be One of the important weapons in the treatment of the millions infected (as expected worldwide)..... Not the only one. A repeat of the images in Italian hospitals must be avoided, otherwise Healthcare will succumb in the developed world The anticipated benefit of SNG001, has forced the company to issue the following statement on their website.... "we have received a number of requests for SNG001 supplies to treat individuals outside the trial. As SNG001 is an experimental drug, untested as to safety and efficacy in this patient group, we regret that we are unable to fulfil any such request at this time."Such requests are not based on whimsical requests of random individuals, but based on the collective demand from leading clinicians. Given the perceived benefit of this inhaled drug, I anticipate that the company, whilst awaiting good clinical data from well designed studies, will actually make this drug available for "off-label" use on a named patient basis (this is frequently how some patients get the treatment before it is formally licensed) Apologies for the length of the comment, but I hope it is of use, and I am on lock down and bored with no live sport... I'm at risk of having a conversation with my wife!!!!!! | yet another final | |
21/3/2020 13:46 | I would suggest just above 50p. I certainly hope it's not above 58p because I won't have enough to get my extra 1000 shares. I like round numbers so would really struggle to buy 950.... | nobbygnome | |
21/3/2020 13:45 | What price will it cost me to top up on Monday morning.?BTW whatever it is l will still be buying,but will obviously get far less if it booms. | bmnsa | |
21/3/2020 13:43 | SNG have the right product at the right time and will make a fortune........if it works! | nobbygnome | |
21/3/2020 13:42 | Thanks for the prompt replies So we have a)treatment, b) testing kit and c) vaccine ( a long way off) Seems incredible that a treatment cure is a possibility | lukead | |
21/3/2020 13:36 | Nyct has very good testing kits for covid-19 and supplying them globally. SNG have a treatment for asthmatic (lung conditions) already past stringent tests which is currently also being trialled and fast tracked for covid-19 patients. If successful this will multi bag many many times from here. Interestingly, ncyt just recieved FDA approval which will see it massively gap up on Monday morning and lots of fresh cash coming into here chasing a very very tight free float. I believe we will see a three digit percentage rise both here and at ncyt on Monday. | likya123 | |
21/3/2020 13:34 | You are comparing apples and pears. NCYT is making a test and SNG a treatment so completely different products. I know which one I would rather own shares in but each to their own. | nobbygnome | |
21/3/2020 13:29 | Forgive my ignorance, but I have just stumbled across this share and NCYT, the PM is talking about a vaccine in about 12 months time or longer. Can anyone answer 1) Are both SNG and NCYT both testing for an actual cure to the virus, as opposed to a preventative medicine? 2) presumably both companies have merits, what are the main differences? 3) is it a case of buying both or is one better placed than the other? Thanks | lukead | |
21/3/2020 13:01 | No you cannot, it is set. | bmnsa | |
21/3/2020 12:36 | well you can add to it...and you have used a question mark.... | hazl | |
21/3/2020 12:35 | 'The biotech will begin a phase 2 trial in COVID-19, after an initial pilot phase of the study involving 100 patients, which is set to take place across a number of NHS trusts and has also been adopted by the NIHR Respiratory Translational Research Collaboration. “The UK life science ecosystem is stepping up across the piece on coronavirus. It’s fantastic to see a small UK biotech company, Synairgen starting UK clinical trials immediately on COVID-19,” commented Steve Bates, CEO of the UK BioIndustry Association. "This shows the speed at which our ecosystem can move; linking SMEs, the established UK clinical trials infrastructure of the NHS and an enabling regulator in the UK’s MHRA. “The sector is also working flat out on innovative emergent ventilator capacity, novel vaccine scale-up capacity, new ways to support NHS patients at home with digital products and investigating antibody technology for therapeutic use,” he added.' | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions